Skip to content

A Pilot Study of Creative Arts Interventions for Neurology Inpatients

A Pilot Study of Creative Arts Interventions for Neurology Inpatients in the Epilepsy Monitoring Unit and the Headache Service

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03520777
Enrollment
33
Registered
2018-05-11
Start date
2017-09-19
Completion date
2018-06-30
Last updated
2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Migraine

Brief summary

The purpose of the study is to assess the feasibility of a Creative Artists Program intervention with epilepsy and headache patients admitted to Dartmouth-Hitchcock Medical Center for care by the Department of Neurology.

Detailed description

Qualifying patients admitted to Epilepsy monitoring or Headache treatment will be approached for participation in the study. Patients who consent to the study will be given a chance to work with one of three creative artists (visual artist, creative writer, therapeutic musician). The artist will be selected according to a pre-determined schedule, and the arts intervention may last up to 90 minutes. Subjects will be asked to complete study questionnaires before and after the arts intervention.

Interventions

OTHERArt Intervention

Type of artist intervention will be determined by the subject and the assigned artist.

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> or = 18 years 2. Diagnosis of refractory chronic epilepsy, status migrainosus, or chronic daily headache 3. Elective admission to the Dartmouth-Hitchcock Medical Center Epilepsy monitoring unit or Headache service 4. Capable of giving informed consent

Exclusion criteria

1. Active psychiatric illness that prohibits safe visitation by artists 2. Impairment of vision or hearing that would prohibit able to participate with participation in instructions necessary for the interventions. 3. Active general medical condition that would impair consciousness.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of conducting a creative arts intervention studyThrough study completion, approximately 1 yearThe feasibility of the creative intervention will be determined by the completion rates of the initial intervention attempts. If less than 50% of patients complete the intervention it will be deemed unfeasible in the current format.

Secondary

MeasureTime frameDescription
Change in patient anxiety before and after the interventionEach patient will be assessed at baseline (Day 1) and after the intervention (approximately Day 3 - 21).Change in anxiety level will be calculated, based on patient questionnaire responses, following the creative intervention.
Change in patient distress before and after the interventionEach patient will be assessed at baseline (Day 1) and after the intervention (approximately Day 3 - 21).Change in distress level will be calculated, based on patient questionnaire responses, following the creative intervention.
Change in patient depression before and after the interventionEach patient will be assessed at baseline (Day 1) and after the intervention (approximately Day 3 - 21).Change in depression level will be calculated, based on patient questionnaire responses, following the creative intervention.
Change in frequency of as-needed pain medication useEach patient as-needed medication use will be assessed after the arts intervention and until discharge from the hospital (approximately Day 3 - 21).As-needed pain medication utilization will be evaluated following the creative arts intervention through subject discharge.
Length of hospital stayEach patient's admission duration (approximately 3 - 21 Days).Length of hospital stay will be calculated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026